阿肯色州 的 非小细胞肺癌 临床试验
阿肯色州 有 34 项针对 非小细胞肺癌 的研究正在招募参与者。
阿肯色州 的城市
官方研究文本（英文）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT07293247A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Highlands Oncology Group - Springdale /ID# 277132, Springdale
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT07155187Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月1日 · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Highlands Oncology Group, PA, Fayetteville
- Highlands Oncology Group, PA, Rogers
- Highlands Oncology Group, PA, Springdale
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
- Highlands Oncology Group-Research Department ( Site 0062), Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Highlands Oncology Group, Fayetteville
- Highlands Oncology Group, Rogers
- Highlands Oncology Group, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07222566Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Highlands Oncology Group, PA, Fayetteville
- Highlands Oncology Group, PA, Rogers
- Highlands Oncology Group, PA, Springdale
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07227298Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Highlands Oncology Group, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06890598Pan-tumor MRD Study
- CARTI, Little Rock
- Highlands Oncology Group (HOG), Springdale
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT03191149Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Little Rock
- Research Site, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06357533Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Little Rock
招募中2 期
18 至 95 岁 · 所有性别 · 更新于 2026年9月23日 · NCT05061550A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- University of Arkansas for Medical Sciences /ID# 272923, Little Rock
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06568939A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0686, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06875310A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Hot Springs
- Clinical Study Sites, Jonesboro
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Highlands Oncology Group - Springdale, Springdale
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT04613596A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Highlands Oncology Group, Springdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月8日 · NCT06119581Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- CARTI Cancer Center ( Site 0006), Little Rock
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月3日 · NCT06422143Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Arkansas for Medical Sciences, Little Rock
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年8月17日 · NCT06500481Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- University of Arkansas, Little Rock
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月5日 · NCT07444814Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
- Highlands Oncology Group, Springdale
招募中3 期
18 至 90 岁 · 所有性别 · 更新于 2026年7月27日 · NCT06745908A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Highlands Oncology Group, Fayetteville
- Highlands Oncology Group, Rogers
- Highlands Oncology Group, Springdale
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年7月6日 · NCT04389632Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Mercy Hospital - FTS, Fort Smith
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年6月29日 · NCT07327489Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
- University of Arkansas for Medical Sciences, Little Rock
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月3日 · NCT05642572A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Research Site, Fayetteville
招募中3 期
18 至 130 岁 · 所有性别 · 更新于 2026年5月14日 · NCT06417814Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
- University of Arkansas for Medical Sciences, Little Rock
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年5月6日 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
- University of Arkansas for Medical Sciences, Little Rock
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年5月5日 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年5月5日 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mercy Hospital Fort Smith, Fort Smith
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年3月17日 · NCT06418204GEMINI-NSCLC: NSCLC Biomarker Study
- Mercy Clinic Oncology - Fort Smith, Fort Smith
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年2月5日 · NCT05236114SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Little Rock
招募中观察性研究
所有年龄段 · 所有性别 · 更新于 2025年10月28日 · NCT03452774BostonGene and Exigent Genomic INsight Study
- Highlands Oncology Group, Rogers
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2025年2月17日 · NCT06272864数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。